{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T21:30:27Z","timestamp":1786915827579,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.nucmedbio.2023.108367","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T05:08:03Z","timestamp":1689570483000},"page":"108367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Relative Biological Effectiveness (RBE) of [64Cu]Cu and [177Lu]Lu-NOTA-panitumumab F (ab')2 radioimmunotherapeutic agents vs. \u03b3-radiation for decreasing the clonogenic survival in vitro of human pancreatic ductal adenocarcinoma (PDAC) cells"],"prefix":"10.1016","volume":"122-123","author":[{"given":"Amanda J.","family":"Boyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongli","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Crick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Angers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond M.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2023.108367_bb0005","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","article-title":"Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors","volume":"18","author":"Klein","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0010","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12943-020-01167-9","article-title":"PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications","volume":"19","author":"Zhu","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102016","article-title":"Immunotherapy for pancreatic cancer: a 2020 update","volume":"86","author":"Schizas","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0025","author":"American Cancer Society"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0030","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1053\/j.seminoncol.2021.02.005","article-title":"Radiotherapy for locally advanced pancreatic ductal adenocarcinoma","volume":"48","author":"Buss","year":"2021","journal-title":"Semin Oncol"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0035","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/cncr.32756","article-title":"Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): an international systematic review and meta-analysis","volume":"126","author":"Tchelebi","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0040","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.16272.1","article-title":"Recent advances in radiation therapy of pancreatic cancer","volume":"7","author":"Venkatesulu","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0045","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s12029-016-9909-2","article-title":"Five-fraction stereotactic body radiation therapy (SBRT) and chemotherapy for the local management of metastatic pancreatic cancer","volume":"49","author":"Lischalk","year":"2018","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0050","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrc3925","article-title":"Radioimmunotherapy of human tumours","volume":"15","author":"Larson","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2015.12.003","article-title":"Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting alpha-particles or Auger electrons","volume":"109","author":"Aghevlian","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0060","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.ijrobp.2003.09.098","article-title":"Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody","volume":"58","author":"Foon","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0065","doi-asserted-by":"crossref","first-page":"802","DOI":"10.2174\/138945012800564158","article-title":"Targeting EGFR in pancreatic cancer treatment","volume":"13","author":"Troiani","year":"2012","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s41181-020-00111-y","article-title":"Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD\/SCID or NRG mice with panitumumab labeled with Auger electron emitting, 111In or beta-particle emitting, 177Lu","volume":"5","author":"Aghevlian","year":"2020","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41181-019-0075-2","article-title":"Auger electrons for cancer therapy - a review","volume":"4","author":"Ku","year":"2019","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0080","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1089\/ars.2015.6309","article-title":"Localized irradiation of cell membrane by Auger electrons iscytotoxic through oxidative stress-mediated nontargeted effects","volume":"25","author":"Paillas","year":"2016","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0085","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1038\/s41598-021-82812-1","article-title":"Copper-67 radioimmunotheranostics for simultaneous immunotherapy and immuno-SPECT","volume":"11","author":"Hao","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0090","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00259-001-0724-y","article-title":"Copper-67 as a therapeutic nuclide for radioimmunotherapy","volume":"29","author":"Novak-Hofer","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0095","series-title":"MIRD radionuclide data and decay schemes","author":"Eckerman","year":"2008"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0100","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3109\/02841869609104038","article-title":"Auger-electron spectra of radionuclides for therapy and diagnostics","volume":"35","author":"Stepanek","year":"1996","journal-title":"Acta Oncol"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0105","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2967\/jnumed.118.225045","article-title":"64Cu-intraperitoneal radioimmunotherapy: a novel approach for adjuvant treatment in a clinically relevant preclinical model of pancreatic cancer","volume":"60","author":"Yoshii","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.nucmedbio.2014.10.009","article-title":"MicroPET\/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using 64Cu-NOTA-panitumumab F(ab\u2019)2 fragments","volume":"42","author":"Boyle","year":"2015","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0115","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nucmedbio.2020.02.001","article-title":"Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [64Cu]Cu-NOTA-panitumumab F(ab\u2019)2 alone or combined with radiosensitizing gemcitabine and the PARP inhibitor, rucaparib","volume":"84-85","author":"Boyle","year":"2020","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0120","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/09553000902748757","article-title":"Computational analysis of the number, area and density of gamma-H2AX foci in breast cancer cells exposed to 111In-DTPA-hEGF or gamma-rays using Image-J software","volume":"85","author":"Cai","year":"2009","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0125","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gku936","article-title":"Easy quantitative assessment of genome editing by sequence trace decomposition","volume":"42","author":"Brinkman","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0130","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/MPA.0b013e3181c15963","article-title":"Phenotype and genotype of pancreatic cancer cell lines","volume":"39","author":"Deer","year":"2010","journal-title":"Pancreas"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0135","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1073\/pnas.83.14.5141","article-title":"Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer","volume":"83","author":"Korc","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0140","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s00259-006-0189-0","article-title":"123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21WAF-1\/Cip-1","volume":"34","author":"Hu","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0145","first-page":"303","article-title":"Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments","volume":"35","author":"Goddu","year":"1994","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0150","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2967\/jnumed.116.175695","article-title":"Monte Carlo N-Particle (MCNP) modeling of the cellular dosimetry of 64Cu: comparison with MIRDcell S values and implications for studies of its cytotoxic effects","volume":"58","author":"Cai","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181473","article-title":"In vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy","volume":"12","author":"Chan","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncb3452","article-title":"The control of DNA repair by the cell cycle","volume":"19","author":"Hustedt","year":"2016","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0165","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1088\/0031-9155\/41\/10\/001","article-title":"Dose-rate effects in targeted radiotherapy","volume":"41","author":"Dale","year":"1996","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0170","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s13014-020-01697-y","article-title":"The clonogenic assay: robustness of plating efficiency-based analysis is strongly compromised by cellular cooperation","volume":"15","author":"Brix","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0175","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.nucmedbio.2006.11.006","article-title":"Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells","volume":"34","author":"Nayak","year":"2007","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0180","first-page":"23","article-title":"Understanding the radiobiological mechanisms induced by177Lu-DOTATATE in comparison to external beam radiation therapy","author":"Delbart","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0185","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbcan.2017.02.003","article-title":"Biological determinants of radioresistance and their remediation in pancreatic cancer","volume":"1868","author":"Seshacharyulu","year":"2017","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0190","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.molonc.2012.10.002","article-title":"Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity","volume":"7","author":"Porcelli","year":"2013","journal-title":"Mol Oncol"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0195","first-page":"89","article-title":"Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers","volume":"2","author":"Yang","year":"2011","journal-title":"Int J Biochem Mol Biol"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0200","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1038\/s41598-020-60765-1","article-title":"Modification of radiosensitivity by curcumin in human pancreatic cancer cell lines","volume":"10","author":"Schwarz","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0205","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.7150\/thno.82101","article-title":"Imaging DNA damage response by gammaH2AX in vivo predicts treatment response to lutetium-177 radioligand therapy and suggests senescence as a therapeutically desirable outcome","volume":"13","author":"O\u2019Neill","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2023.108367_bb0210","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1021\/acs.molpharmaceut.7b01000","article-title":"Panitumumab modified with metal-chelating polymers (MCP) complexed to 111In and 177Lu - an EGFR-targeted theranostic for pancreatic cancer","volume":"15","author":"Aghevlian","year":"2018","journal-title":"Mol Pharm"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805123000550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805123000550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:31:23Z","timestamp":1760848283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805123000550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":42,"alternative-id":["S0969805123000550"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2023.108367","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relative Biological Effectiveness (RBE) of [64Cu]Cu and [177Lu]Lu-NOTA-panitumumab F (ab')2 radioimmunotherapeutic agents vs. \u03b3-radiation for decreasing the clonogenic survival in vitro of human pancreatic ductal adenocarcinoma (PDAC) cells","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2023.108367","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108367"}}